Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by Don2018on Dec 26, 2019 4:07pm

174 Views

Post# 30491959

RE:Coming up - next level

forhandlaren wrote: I think we'll experience at least the same ride next year (5:1) and break through 2 CAD. Maybe many other investors share the prediction, the expected tax-loss selling has been pretty lame.

0.42/0.43 seems to be very solid, 0.60 in January is not far fetched.

Next year will be a very busy deal year. SGLT2 for pets, multiple for Skin Lightening, perhaps a term sheet for anti-aging and possibly for acne as well. The two last should fit R+F perfectly.

If we get any 2 of those milestones in 2020, you may not be far off with your share price target.
That would be sweet indeed.

Bullboard Posts

Anaergia expands relationship with PepsiCo